X.T.L. Biopharmaceuticals Ltd ADRXTLB
Price$2.30

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $451KTTM through 31 Dec 2024
Net Income -$1MTTM through 31 Dec 2024
Free Cash Flow -$1.7MTTM through 31 Dec 2024

Margins

Current
Gross Margin0.7%
EBITDA Margin-481.4%
Operating Margin-481.6%
Net Margin-227.7%

Returns

-18.9%ROE
-12.0%ROA

Balance Sheet Health

Debt / Equity0.03x
Current Ratio0.61x
Net Debt$240K
Cash & Equivalents$371K

Quality Metrics

Piotroski F-Score2 / 9
FCF Margin-370.7%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'24
FY2024: $451K
Diluted EPS
'18'19'20'21'22'23'24
FY2024: $0.00

Dividend

No dividend

Capital Allocation

Capex Intensity12.0%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.